Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors |
2013-12-19 |
ATMI–Pall Corp: investment, 201312–201402 acquisition $185m net $165m of ATMI Life Sciences by Pall |
2013-12-23 |
AAIPharma Services–Cambridge Major Laboratories: investment, 201312 merger in late 2013 |
2013-12-31 |
Alma Bio Therapeutics–Delphi Genetics: plasmid DNA drugs, 2014– collab strategic alliance w Delphi producing plasmid DNA drugs using Staby technology |
2014-01-01 |
ArchiMed–SEVERAL: investment, 2014 closing of MED I Fund at €150m |
2014-01-01 |
Electrochaea–SEVERAL: investment, 2014 financing round Series A |
2014-01-01 |
genOway–Institut Pasteur: transgenic anmials, 2014– license excl to patent portfolio for technology for transgenic rodent research models |
2014-01-01 |
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon |
2014-01-01 |
Mestex–SEVERAL: investment, 2014 1st financing round |
2014-01-01 |
Optos–Nikon: investment, 2014 acquisition $400m of Optops plc by Nikon |
2014-01-01 |
OxSyBio–SEVERAL: investment, 2014c seed financing round £1m |
2014-01-01 |
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy |
2014-01-01 |
Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m |
2014-01-01 |
Sanofi–MyoKardia: cardiovascular drugs, 2014–201903 collab RnD NOT PROLONGED all rights returned to MyoKardia 201904 |
2014-01-01 |
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR |
2014-01-01 |
Tusk Therapeutics–Droia Ventures: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures |
2014-01-01 |
Cadence Pharmaceuticals–Mallinckrodt: investment, 201402 acquisition $1.3b cash tender offer by Mallinkcrodt plc |
2014-02-11 |
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
Axonics–LCF Rothschild: investment, 201403 investment by EdRIP |
2014-03-01 |
Ono Pharmaceutical–Merus: bispecific antibodies, 201404– collab research + license agreem to develop bispecific ABs for autoimmune diseases |
2014-04-01 |
Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW |
2014-04-15 |
Principia Biopharma–SEVERAL: investment, 201404 financing round Series B $50m led by Sofinnova Ventures |
2014-04-22 |
Principia Biopharma–SEVERAL: investment, earlier than 201404 financing round Series A $40m |
2014-04-22 |
B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania |
2014-06-01 |
Step Pharma–Eurazeo: investment, 201406 founding investor Kurma Biofund II |
2014-06-01 |
Allogene Therapeutics–Pfizer: T-cell immunotherapy, 201804 asset contribution agreem for Pfizer’s allogeneic CAR T immuno-oncology pipeline |
2014-06-18 |
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie |
2014-07-01 |
Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed |
2014-07-15 |
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg |
2014-08-01 |
Paragon Bioservices–Camden Partners: investment, 201410 financing round Series A Preferred Stock led by NewSpring Capital + Camden Partners |
2014-10-01 |
Paragon Bioservices–NewSpring Capital: investment, 201410 financing round Series A Preferred Stock led by NewSpring Capital + Camden Partners |
2014-10-01 |
Paragon Bioservices–SEVERAL: investment, 201410 financing round Series A Preferred Stock led by NewSpring Capital + Camden Partners |
2014-10-01 |
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech |
2014-10-16 |
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery |
2014-11-18 |
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana |
2014-12-01 |
iTeos Therapeutics–Pfizer: investment, 201412 equitiy investment by Pfizer as part of cancer immunotherapy license + collab agreem |
2014-12-08 |
Pfizer–iTeos Therapeutics: cancer immunotherapy, 201412– license for 2 compounds + collab target discovery €24m upfront + investm + milestones et al |
2014-12-08 |
Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures |
2014-12-15 |
Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF |
2014-12-15 |
Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter |
2014-12-15 |
Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures |
2014-12-15 |
Cristal Therapeutics–BioGeneration Ventures: investment, 201412 financing round totalling €6m incl existing investor BGV |
2014-12-15 |
Cristal Therapeutics–Chemelot Ventures: investment, 201412 financing round totalling €6m incl new investor Chemelot Ventures |
2014-12-15 |
Cristal Therapeutics–Limburg (NL) (govt): investment, 201412 financing round totalling €6m incl existing investors Nedermaas + Innovatiefonds Limburg |
2014-12-15 |
Cristal Therapeutics–Thuja Capital: investment, 201412 financing round totalling €6m incl existing investor Thuja Capital |
2014-12-15 |
Cristal Therapeutics–Univ Utrecht: investment, 201412 financing round totalling €6m incl existing investor Utrecht University Holdings |
2014-12-15 |
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG |
2014-12-18 |
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € |
2015-01-01 |
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF |
2015-01-01 |
B Medical Systems–Navis Capital: investment, 2015 acquisition of Medical Dvision of Dometic by Navis Capital creating B Medical Systems |
2015-01-01 |
BIO (US)–Inova Software: business partnering software, 2015– collab using One-on-One for BIO Annual Convention |
2015-01-01 |
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain |
2015-01-01 |
Boston Biotech Conference–Informa: investment, 2015 acquisition 100% £12.7m in cash net of cash acquired |
2015-01-01 |
ClinicPoint–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 |
2015-01-01 |
Corvidia Therapeutics–Sofinnova: investment, 2015 seed financing from Sofinnova Partners |
2015-01-01 |
Enyo Pharma–SEVERAL: investment, 2015 seed financing round €2.2m |
2015-01-01 |
Galgo Medical–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 |
2015-01-01 |
Gemedica Therapeutics–SEVERAL: investment, 2015 funding €2.5m total private investment attracted over the year 2015 |
2015-01-01 |
Greenaltech–SEVERAL: investment, 2015 funding €2m total private investment attracted over the year 2015 |
2015-01-01 |
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors |
2015-01-01 |
iSalud–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 |
2015-01-01 |
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures |
2015-01-01 |
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp |
2015-01-01 |
KSQ Therapeutics–Alexandria Real Estate: investment, 2015–201710 financing totalling $76m incl co-investor Alexandria Equities |
2015-01-01 |
KSQ Therapeutics–ARCH Venture: investment, 2015–201710 financing totalling $76m incl co-investor ARCH Venture Partners |
2015-01-01 |
KSQ Therapeutics–Flagship Pioneering: investment, 2015–201710 financing totalling $76m incl lead + founding investor Flagship Pioneering |
2015-01-01 |
KSQ Therapeutics–Polaris Partners: investment, 2015–201710 financing totalling $76m incl co- + founding investor Polaris Partners |
2015-01-01 |
KSQ Therapeutics–SEVERAL: investment, 2015–201710 financing $76m from Flagship + Polaris + ARCH + Alexandria as KSQ emerges from stealth |
2015-01-01 |
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) |
2015-01-01 |
Medtep–SEVERAL: investment, 2015 funding €1.8m total private investment attracted over the year 2015 |
2015-01-01 |
Morphogen-IX–Cambridge Innovation Capital: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise |
2015-01-01 |
Morphogen-IX–Medicxi Ventures: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise |
2015-01-01 |
Morphogen-IX–SEVERAL: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise |
2015-01-01 |
Morphogen-IX–Univ Cambridge: investment, 2015 seed financing round from Medicxi + Cambridge Innovation Capital + Cambridge Enterprise |
2015-01-01 |
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI |
2015-01-01 |
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI |
2015-01-01 |
Primm Pharma–Xbrane: investment, 2015 acquisition of Primm Pharma srl by Xbrane BioScience AB |
2015-01-01 |
Psious–SEVERAL: investment, 2015 funding €1m total private investment attracted over the year 2015 |
2015-01-01 |
Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research |
2015-01-01 |
Top Doctors–SEVERAL: investment, 2015 funding €1.1m total private investment attracted over the year 2015 |
2015-01-01 |
Transplant Biomedicals–SEVERAL: investment, 2015 funding €1.5m total private investment attracted over the year 2015 |
2015-01-01 |
VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB |
2015-01-01 |
ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme |
2015-01-01 |
Baxalta–Symphogen: cancer immunotherapy, 201601– collab strategic ww €160m upfront + €1.4b milestones + roaylties in immuno-oncology |
2015-01-04 |
Alcobra–LifeSci: public relations, 201501 service existent US investor relations by LifeSci Advisors |
2015-01-09 |
Alcobra–Sam Brown: public relations, 201501 service existent by Sam Brown Inc |
2015-01-09 |
Fluidic Analytics–SEVERAL: investment, 201501 financing round Series A £1.56m ($2.4m) led by Cambridge Enterprise |
2015-01-12 |
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion RnD small-molecule KRAS inhibitors for cancer |
2015-01-13 |
HiberGene–SEVERAL: investment, 201502 financing round Series A €2m |
2015-02-01 |
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m |
2015-02-01 |
G1 Therapeutics–SEVERAL: investment, 201502 financing round Series B $33m co-led by Eshelman Ventures + RA Capital Management |
2015-02-05 |
Synthace–SEVERAL: investment, 201502 financing round £2.2m incl SOSventures + Bioeconomy Capital et al |
2015-02-11 |
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m |
2015-03-01 |
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit |
2015-03-03 |
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital |
2015-03-04 |
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne |
2015-03-04 |
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund |
2015-03-04 |